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0959-8049/ª 2018 Elsevier Ltd. All righAbstract Background: Head and neck squamous cell carcinoma (HNSCC) is the 6th most
common cancer with approximately half a million cases diagnosed each year worldwide.
HNSCC has a poor survival rate which has not improved for over 30 years. The molecular
pathogenesis of HNSCCs remains largely unresolved; there is high prevalence of p53 muta-
tions and EGFR overexpression; however, the contribution of these molecular changes to dis-
ease development and/or progression remains unknown. We have recently identified
microRNA miR-196a to be highly overexpressed in HNSCC with poor prognosis. Oncogenic
miR-196a directly targets Annexin A1 (ANXA1). Although increased ANXA1 expression
levels have been associated with breast cancer development, its role in HNSCC is debatable
and its functional contribution to HNSCC development remains unclear.
Methods: ANXA1 mRNA and protein expression levels were determined by RNA Seq anal-
ysis and immunohistochemistry, respectively. Gain- and loss-of-function studies were per-
formed to analyse the effects of ANXA1 modulation on cell proliferation, mechanism off Molecular Oncology, King’s College London, Guy’s Hospital Campus, Hodgkin Building, London SE1
kcl.ac.uk (M. Tavassoli).
3
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N. Raulf et al. / European Journal of Cancer 102 (2018) 52e68 53activation of EGFR signalling as well as on exosome production and exosomal phospho-
EGFR.
Results: ANXA1 was found to be downregulated in head and neck cancer tissues, both at
mRNA and protein level. Its anti-proliferative effects were mediated through the intracellular
form of the protein. Importantly, ANXA1 downregulation resulted in increased phosphoryla-
tion and activity of EGFR and its downstream PI3K-AKT signalling. Additionally, ANXA1
modulation affected exosome production and influenced the release of exosomal phospho-
EGFR.
Conclusions: ANXA1 acts as a tumour suppressor in HNSCC. It is involved in the regulation
of EGFR activity and exosomal phospho-EGFR release and could be an important prog-
nostic biomarker.
ª 2018 Elsevier Ltd. All rights reserved.1. Introduction
Every year nearly 600,000 new cases of head and neck
cancer are diagnosed worldwide, which equals over 1451
cases every day [1]. Incidence rates are rising, and most
patients present with advanced stages of the disease which
negatively impacts treatment success [1,2]. Additionally,
the molecular pathways involved in the development and
progression of head and neck squamous cell carcinomas
(HNSCC) remain largely unknown. Therefore, there is an
important need to identify predictive and prognostic bio-
markers and understand their functional contribution to
HNSCC development. We recently identified Annexin A1
(ANXA1) as a target of the oncogenic microRNA miR-
196a [3]. The 37 kDa ANXA1 (also known as lipocortin-
1) is a member of the annexin superfamily of proteins,
which contains multiple calcium and phospholipid-
binding proteins implicated in a broad range of cellular
functions [4,5]. ANXA1 exists in two major formsda
secreted extracellular (cleaved) protein and a full-length
intracellular protein [6]. Originally, ANXA1 was identi-
fied as a glucocorticoid-regulated anti-inflammatory pro-
tein with important functions in the innate and adaptive
immune response [7]. These activities were mainly attrib-
uted to the externalised form of ANXA1 and are mediated
by binding of the protein to formyl peptide receptors
(FPRs), 7 transmembrane domain and G pro-
teinecoupled receptors [7]. In contrast to the mainly anti-
inflammatory functions of secreted ANXA1, the full-
length intracellular protein has been associated with a
wide range of cellular functions such as cytoskeletal
organisation, plasma membrane repair, autophagy and
intracellular calcium signalling as well as lipid-mediated
signalling pathways [8e11]. Different intracellular local-
isations and stimulus- or modification-dependent re-
distributions of the ANXA1 protein have been observed
[12,13]. A role of ANXA1 in tumour development and
progression has been described for different cancer sub-
types. While in most cancer types such as breast, cervical,
hepatic and pancreatic cancer high levels of ANXA1 havebeen associated with more aggressive disease, its role in
HNSCC remains debatable [14e19]. Interestingly, one of
the main risk factors of oral cancer, chewing tobacco, re-
sults in the loss of the anti-inflammatory activity of
ANXA1 rather than its increase [20].
In recent years, ANXA1 has been linked to epidermal
growth factor receptor signalling in cervical cancer [21].
Epidermal growth factor receptor (EGFR), also known
as Her1 or ErbB-1, is a receptor tyrosine kinase
belonging to the ErbB family of receptors, which also
includes ErbB-2, ErbB-3 and ErbB-4 [22]. EGFR is
widely considered to be one of the central drivers of
oncogenesis in HNSCC [23]. More than 80% of HNSCC
cases exhibit an increased membraneous expression of
EGFR, and overexpression of the receptor is linked to
radiotherapy-resistance mechanisms [24,25]. Natural li-
gands of EGFR are growth factors, including EGF and
TGF-a [26,27]. Ligand binding results in receptor
phosphorylation and activation, although ligand-
independent and constitutive EGFR signalling have
also been described [28,29]. EGFR activation steers
among others JAK/STAT signalling as well as the PI3K/
AKT, the RAS/RAF/ERK and the PLC/PKC pathways
controlling processes including DNA repair, prolifera-
tion, angiogenesis, and inhibition of apoptosis [30].
Several EGFR-targeting drugs have been developed.
One of these drugs is cetuximab, an IgG1-chimerised
aEGFR monoclonal antibody with high affinity for the
extracellular EGF domain of EGFR and thereby pre-
venting ligand binding and receptor activation [31].
However, EGFR targeted drugs so far have shown very
limited effect in HNSCC.
Depending on the type of ligand, ligand-activated
EGFR can signal from various subcellular compart-
ments unless it is sequestered on intraluminal vesicles
(ILVs) in the lumen of multivesicular endosomes where
it is delivered to lysosomes for degradation [32].
ANXA1 has been suggested to be important for the
formation of the intraluminal vesicles and thus termi-
nation of EGFR signalling in cervical cancer [33,34].
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cles called exosomes [35]. Interestingly, in addition to its
intracellular function, lately, a role of extracellular
exosomal EGFR in metastasis formation and tumour
immunity has been described [36,37]. In this study, we
have investigated the involvement of ANXA1 in
HNSCC with the aim of exploiting its potential as a
prognostic/predictive biomarker and/or therapeutic
target in the cancers of head and neck.2. Materials and methods
2.1. Cell lines and tissue culture
The cell lines included in this study were HEK293T cells,
the head and neck squamous cell carcinoma (HNSCC)
cell lines HN5, HN30, HSC3, H357, UTSCC-34,
UTSCC-6A, SCC-22B as well as the breast cancer cell
line MCF-7. UTSCC-34 and UTSCC-6A cells were
provided by Professor Reidar Grenman, Department of
Otorhinolaryngology, Head and Neck Surgery, Turku
University and Turku University Hospital, Turku,
Finland; SCC-22B cells by Dr. Thomas Carey, Univer-
sity of Michigan, USA; and H357 cells by Dr. Stephen
Prime, Department of Oral and Dental Science, Uni-
versity of Bristol, Bristol, UK. HN5 and HSC3 cells
were obtained from Professor Barry Gusterson,
Department of Pathology, University of Glasgow, UK
and Dr. Kazuya Tominaga, Department of Oral Pa-
thology, Osaka Dental University, Japan, respectively.
HN30 cells were provided by Dr. Andrew Yeudall,
Philips Institute of Oral and Craniofacial Molecular
Biology, Virginia Commonwealth University, Rich-
mond, Virginia, USA. HEK293T cells which were used
for retrovirus and lentivirus production were a gift from
Dr. Lucas Chan, Rayne Institute, King’s College Lon-
don, UK. All cell lines except H357, UTSCC-34, and
UTSCC-6A were maintained in Dulbecco’s Modified
Eagles Medium (DMEM; GE Healthcare, Chalfont St.
Giles, UK) supplemented with 10% foetal bovine serum
(FBS), 50-mg/ml streptomycin, 100-mg/ml penicillin and
1 mM sodium pyruvate. UTSCC-34 and UTSCC-6A
cells were maintained in DMEM (GE Healthcare,
Chalfont St. Giles, UK) supplemented with 10% FBS,
2 mM L-glutamine, 5-ml nonessential amino acids, 125-
mg/ml streptomycin and 250-mg/ml penicillin. For H357
cells, DMEM-F12 supplemented with 10% FBS, 4 mM
L-glutamine, 69 nM hydrocortisone, 50-mg/ml strepto-
mycin, 100 mg/ml penicillin and 1 mM sodium pyruvate
was used. The expression of ANXA1 was stably
modulated in selected HNSCC cell lines. Lentiviral
constructs used for downregulation of ANXA1 have
been described previously [3]. Sh-scrambled control and
sh-ANXA1 expressing cells were selected using 2 mg/ml
puromycin. For treatment with recombinant EGF
(Peprotech, London, UK), 500,000 cells per well wereseeded in a 6-well plate. The next day, cells were serum-
starved and 24 h later treated with 50e200 ng/ml re-
combinant EGF (in 5% trehalose) or 5% trehalose only
for the indicated time points. For cellular proliferation
studies with recombinant ANXA1, 100 nM recombinant
ANXA1 were included. Recombinant ANXA1 was
provided by Prof Mauro Perretti, William Harvey
Research Institute, Barts and The London School of
Medicine, Queen Mary University of London, UK.
pLenti-puro-hANXA1-FL was a kind gift from Dr. Egle
Solito, William Harvey Research Institute, Barts and the
London School of Medicine and Dentistry, Queen Mary
University of London, UK.
2.2. Western blot analysis
Immunoblotting was performed as described previously
[38]. Briefly, cells were lysed in lysis buffer (1 mMMgCl2,
12.5 mM HEPES/KOH, pH 7.4, 1 mM EGTA, 1%
Triton-X100) or 10 RIPA buffer (exosomes) including
protease inhibitors. Protein concentrationwas determined
byBradford assay, and 25e50mg of proteinwas separated
on 8e15% 1.5 mm thick SDS-gels and transferred to
nitrocellulose membranes (400 mA, 90 min) using the
Mini-PROTEAN electrophoresis system combined with
the Mini-Trans Blot module (Bio-Rad, Hercules, CA,
USA). Afterwards membranes were probed with the an-
tibodies of choice. Antibodies used for immunoblotting
were beta-actin, alpha-tubulin (SigmaeAldrich, St.Louis,
MO,USA), EGFRF4, phospho-ERK1/2, phospho-AKT
(Ser473) phospho-EGFR (Tyr1068), pan-AKT, phospho-
STAT3 (Tyr705), pan-STAT3, ANXA1 (Cell Signaling,
Danvers, MA, USA) and CD63 (MEM-259, GeneTex,
Inc., Irvine, CA, USA). Antibodies were used at a con-
centration of 1:1000 or 1:5000 (beta-actin, alpha-tubulin).
Secondary HRP-coupled anti-rabbit (1:2000) and anti-
mouse antibodies (1:1000) were obtained from Fisher
Scientific (Loughborough, UK) and SigmaeAldrich (St.
Louis, MO, USA), respectively.
2.3. Immunofluorescence
30,000 cells were seeded in duplicate in 8-chamber slides
(BD Biosciences, San Jose, CA, USA). The next day,
cells were washed twice with 1 PBS and fixed in 4%
paraformaldehyde for 15 min. Following 2 washing step
with 1 PBS, cells were permeabilised for 15 min using
0.2% Triton-X100, then washed again and incubated for
30 min in 3% bovine serum albumin (BSA) in TBS-
Tween. Cells were incubated at 4 C overnight under
constant agitation in antibodies of choice (diluted in 3%
BSA in TBS-Tween) or 3% BSA in TBS-Tween only as
negative control. Afterwards, cells were washed twice
using 1 PBS and then incubated with secondary fluo-
rescently tagged antibody for 90 min at 37 C protected
from light. Following several washing steps in 1 PBS,
the chambers were removed from the slides, and cells
Tissue Healthy (total) Tumour (total)
Bladder urothelial carcinoma 19 414
Breast invasive carcinoma 113 1119
Colon adenocarcinoma 41 483
Glioblastoma multiforme 5 170
Head and neck squamous carcinoma 44 504
Kidney renal clear cell carcinoma 72 542
Kidney renal papillary cell carcinoma 32 291
Liver hepatocellular carcinoma 50 374
Lung adenocarcinoma 59 541
Lung squamous cell carcinoma 51 502
Prostate adenocarcinoma 52 502
Stomach adenocarcinoma 37 420
Uterine corpus endometrial carcinoma 35 554
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taining 40,6-diamidin-2-phenylindole (DAPI; Vector
Laboratories; Burlingame, CA, USA). Images were ac-
quired on an Olympus BX61 at 60 magnification.
Antibodies used for immunofluorescence were EGFR
F4 and FPR2. The FPR2 antibody was kindly provided
by Prof Mauro Perretti, William Harvey Research
Institute, Barts and The London School of Medicine,
Queen Mary University of London, UK.
2.4. Lentiviral-based expression modulation
ANXA1 knockdown and scrambled control cells were
generated as described previously [3]. Virus was pro-
duced in HEK293T cells. Viral supernatant was har-
vested after 24, 36, and 48 h, filtered through a 0.45 mm
filter and immediately used for transduction of target
cells. Cells were selected based on their newly acquired
antibiotic resistance.
2.5. Cell proliferation assay
30,000 cells per well were seeded in triplicate in 6-well
plates. Over the following 5 d, cells were trypsinised and
counted using aNeubauer chamber. Cell proliferationwas
also assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) cell viability assay.
Stably modulated cells were seeded in a 96-well plate
(2000 cells in 150 ml medium per well), 6 wells per time
point. The next day, the medium was replaced with 150 ml
DMEM  100 nM recombinant ANXA1 or different
concentrations of recombinant EGF (0.5, 5 and 50 ng/ml)
using trehalose as vehicle control. For the following 5 d,
20 ml MTT solution (Calbiochem, Watford, UK; 5 mg/ml
MTT in 1 PBS) was added to each well, and after 2 h of
incubation, 150-ml solubilisation solution (50% dime-
thylformamide, 0.2% glacial acetic acid, 20 mMHCl, 20%
SDS)was added.After incubation over night, theOD595nm
was measured on a Tecan Infinite F50.Medium 100 nM
recombinant ANXA1 or recombinant EGF was renewed
daily over the course of the experiment.
2.6. Cell viability assay (cetuximab)
Cells were seeded in 96-well plates at a density of
6000 cells per well. The next day, cells were treated with
cetuximab (Erbitux, Merck KGaA, Darmstadt, Ger-
many), and cell viability was assessed after the indicated
time points by adding 20 ml of MTT solution, and after
1e2 h of incubation, 150 ml of solubilisation solution
was added to each well. Following overnight incubation,
OD595nm was measured using a Tecan Infinite F50.
2.7. RNA seq
Publicly available RNA sequencing data from The Cancer
Genome Atlas (TCGA) was used (GSE62944) to compareANXA1 gene expression (FPKM values) between healthy
and tumour samples from 13 different tissues [39]. The
following tissues were used for the study:The processed FPKM values from healthy and
tumour tissues were log2 transformed and implemented
to the Linear Models for Microarray Data (limma) for
differential expression analysis [40]. The limma-trend
method was used by inputting the log2-FPKM values
into limma’s standard pipeline, with trendZ TRUE for
the empirical Bayes function. Limma uses an eBayes
t-test that takes into account the global variance to
minimise the influence of noise of local variance for
small samples.
2.8. Immunohistochemistry
Immunohistochemical staining on head and neck cancer
tissue samples was previously approved by the UK
National Research Ethics Service (Reference: 10/H0701/
27). Forty-one consecutive patients with oropharyngeal
squamous cell carcinoma were retrospectively identified
from pathology databases. Following review by a
specialist head and neck pathologist, 4 mm paraffin
sections were routinely prepared. ANXA1 (Clone
MRQ-3), EGFR extracellular domain (Clone 3C6) and
EGFR intracellular domain (Clone 5B7) immunohisto-
chemical staining was undertaken using prediluted
proprietary kit (Clone MRQ-3, Ventana Medical Sys-
tems) on a Ventana Benchmark Autostainer (Ventana
Medical Systems) according to manufacturer in-
structions. Oral squamous cell carcinoma and splenic
hairy cell leukaemia were used as positive controls for
EGFR and ANXA1, respectively. Omission of the pri-
mary antibody served as negative controls.
All cases were independently scored by at least two
observers. Where present, the non-dysplastic surface or
reticulated crypt epithelium was taken as the referent. An
ordinate value of 0e3 was assigned to the intensity of
nuclear staining. The percentage of each intensity was
allotted to the entire tumour within the whole mount
tissue section and a product of each intensity value and its
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nuclear ‘H-Score’ was then determined using the
following formula: [(1% cells intensity 1) þ (2% cell
intensity 2) þ (3% cells intensity 3)]. A cytoplasmic ‘H-
Score’ was obtained in a similar way. As it was not
possible to differentiate varying intensities of membrane
staining, the percentage of any membrane positivity was
scored i.e. a binary allocation of 1 (membrane positive
cells) or 0 (membrane negative cells) was allotted to the
entire tumour within the whole mount tissue section.Fig. 1. ANXA1 is downregulated in head and neck cancer, which r
independently of FPR2 signalling. (A) The FPKM levels of ANXA1
boxplots. Median and 25% and 75% quantiles are shown as box, 5% an
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Fig. 1. (continued).
N. Raulf et al. / European Journal of Cancer 102 (2018) 52e68 57defined as (nuclear H-Score) þ (cytoplasmic H-
Score)þ (%membrane staining) to give a range of 0e700.
2.9. Protein precipitation using trichloracetic acid (TCA)
Cells were seeded in 6-well plates at a density of 300,000
cells per well. Forty-eight h later, the supernatant of the
cells was harvested and centrifuged for 5 min at
3000 rpm. Proteins present in the supernatant were
precipitated using TCA as described previously. Briefly,
one volume of 100% (w/v) TCA (SigmaeAldrich, St.
Louis, MO, USA) was added to 4 volumes of protein
sample and incubated on ice for 30 min. Samples were
centrifuged for 10 min at 13,200 rpm (4 C), and thepellet was washed twice with 500 ml ice-cold acetone.
Afterwards, the pellet was dried for 5 min in a heat
block (95 C), 45 ml 2 LSB was subsequently added,
and the pH was restored using 5 ml 1.5 M Tris, pH 8.8.
25 ml of the sample was analysed by immunoblotting.
Additionally, the adherent cells were trypsinised,
washed once with 1 PBS, and a whole-cell lysate was
prepared. Whole-cell lysate (40 mg) was used for
immunoblotting.
2.10. Exosome isolation
5  106 HN5 Ctrl or ANXA1 knockdown cells were
seeded in T75 flasks, in 10 ml medium per flask, 7 flasks
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and once with DMEM w/o FCS. Finally, 10 ml DMEM
including 10% bovine exo-free FBS (as well as pen/strep)
were added to each flask. After 48 h, the medium was
centrifuged for 20 min at 300g followed by centrifuga-
tion at 2000g for 20 min (both: 4 C). The supernatant
was stored at 80 C until further analysis. The super-
natant was thawed slowly over night at 4 C, centrifuged
at 12200g for 45 min (4 C), and then filtered with a
0.45 mm filter followed by ultracentrifugation (100,000g
for 2 h at 4 C). The exosome pellet was sequentially
resuspended in sterile PBS and ultracentrifuged at
100,000g for 90 min (4 C). After this washing step, the
exosome pellet was resuspended in 200 ml sterile PBS and
stored at 80 C until further analysis.
2.11. Nanoparticle tracking analysis
Exosome preparations which were stored at 80 C
were thawed slowly on ice. A 1:500 dilution (in PBS) was
prepared. Nanoparticle tracking analysis (NTA) is
based on the principle that the rate of Brownian
movement of nanoparticles in solution is a function of
their size [41]. In this method, a laser beam is directed at
a fixed angle to the vesicle suspension, and the side-
scattered light is captured using a standard microscope
and high-sensitivity camera. By tracking the Brownian
movement of individual nanoparticles over time, a
software (NTA 3.1, Malvern, Ltd) calculates their
diameter given a known temperature and viscosity of the
sample. One advantage of this method is the ability to
measure size distribution in polydisperse samples. Exo-
some analysis was carried out as previously described
[42]. Briefly, exosome preparations were diluted to a
final volume of 1 ml of 0.45 mmefiltered sterile PBS and
examined using a Nanosight LM10-HS system fitted
with an LM14 laser unit-temperature module control
(Malvern, Ltd) and with a syringe pump (Harvard
Apparatus, Cat No 98-4730) at a constant flow injection
of 60 A.U. Individual dilutions were standardised for
each cell line and finally used at 1:100e1:200 of exosome
preparation over PBS for optimal particle-per-frame
performance of NTA. Five video recordings of 30 s
each were captured using automatic laser intensity and
camera level per individual sample. Tracking thresh-
olding was manually adjusted for each sample and kept
to a minimum value in order to ensure the tracking of all
particles and to avoid noise-related artefacts. The videos
were analysed, and particle modal size and concentra-
tion was calculated. Each condition was repeated in 3
independent experiments.
2.12. Statistical analysis and software
Statistical analysis of experimental data was performed
using GraphPad Prism 6 software (Graphpad Software
Inc., La Jolla, CA, USA), and data were comparedusing 1-way ANOVA or unpaired student’s t-test. Data
of at least 3 independent experiments are presented as
mean  standard error of the mean (SEM) unless
otherwise stated. p-values less than 0.05 were considered
statistically significant. The bioinformatic results pre-
sented in this article were obtained using R version 3.3,
Bioconductor version 3.3 and the software packages
limma 3.28.6.3. Results
3.1. ANXA1 is downregulated in HNSCC and this
mediates an oncogenic phenotype
We recently showed that ANXA1 is a direct target of
the oncogenic microRNA miR-196a in HNSCC cell
lines [3]. To determine ANXA1 expression levels in
head and neck tumours, RNA Seq data of 504 tumour
samples and 44 healthy controls was compared.
ANXA1 expression was found significantly down-
regulated in tumour samples (Fig. 1A). Furthermore,
there is a clear correlation between ANXA1 expression
and tumour progression from G1 to G4. There is a
decrease in ANXA1 in G2 compared to G1, with a
further reduction in G3 (Fig. 1B and Supplemental
Table 1). To confirm the RNA Seq data, we evaluated
ANXA1 protein expression by IHC in 41 oropharyn-
geal squamous cell carcinoma patient tissue samples.
Intrasectional adjacent non-dysplastic surface and
reticulated crypt epithelium consistently demonstrated
high ANXA1 levels (mean total ANXA1 H
score Z 455, median total ANXA1 H score Z 460;
Fig. 1C and D). By contrast, ANXA1 protein levels
were consistently decreased in the tumours when
compared to intrasectional adjacent non-dysplastic
surface and reticulated crypt epithelium (p < 0.0001,
independent t-test, mean total ANXA1 H scoreZ 127,
median total ANXA1 H score Z 80; Fig. 1E and F
and Supplemental Fig. S1A and B as well as
Fig. 1G). Functional studies using shRNA to knock-
down ANXA1 resulted in a clear increase in cellular
proliferation in 4 different HNSCC cell lines (UTSCC-
34 and USCC-22B Ctrl and ANXA1, Suppl. S2A and
B; HN5 and HN30 Ctrl and ANXA1 knockdown
cells, see Fig. 1I). We also attempted to overexpress
ANXA1 in HNSCC cell lines using various approaches.
Although overexpression of the ANXA1 construct
increased the ANXA1 protein levels in 293T cells and
GFP as the transfection positive control in HNSCC cell
lines was successful, we were unable to overexpress
ANXA1 in several HNSCC cell lines (see Suppl.
S3AeC). This further supports a growth suppressor
role for ANXA1 in HNSCC.
Cleavage and secretion of ANXA1 have recently been
reported [16,43]. Extracellular ANXA1 acts as ligand for
the formyl peptide receptors FPR1 and FPR2, and
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cellular proliferation and migration [44]. Immunoblot
analysis of the HNSCC cell lines used in this study
indicated the expression of a shorter cleaved 33 kDaFig. 2. ANXA1 regulates EGFR signalling. (A) ANXA1 and EGFR n
from MetaCore. (B-E) Representative photomicrograph of intracellu
C: medium power view, scale bar Z 200 mm) and ANXA1 (D: whole
bar Z 200 mm) immunohistochemistry in the same head and neck
epithelium is present at the top (B, D) and top right (C, E) while carcin
magnifications of B and D are shown in C and E, respectively.version of ANXA1 in addition to the full-length 37 kDa
protein (Fig. 1H). Importantly, the 33 kDa, cleaved
version of ANXA1 was also greatly diminished in the
ANXA1 knockdown cell lines compared to vectoretwork reconstruction based on the literature knowledge obtained
lar domain of EGFR (B: whole mount view, scale bar Z 500 mm;
mount view, scale bar Z 500 mm; E: medium power view, scale
squamous cell carcinoma tissue sample. Non-dysplastic surface
oma is present in the lower part of each photomicrographs. Higher
Fig. 3. Downregulation of ANXA1 results in increased and prolonged activation of EGFR signalling. (A) HN5 Ctrl and ANXA1 KD1
cells were stained for total EGFR, and DAPI was used as nuclear marker. Images were taken at 60 magnification. (B) HN5 Ctrl and
ANXA1 KD1 cells were treated with different concentrations of recombinant EGF or 5% trehalose (Treh) as vehicle control for 30 min,
and the levels of total EGFR and EGFR phosphorylated on tyrosine 1068 were analysed by immunoblotting. Tubulin served as loading
control. The results of one exemplary immunoblot (n Z 3) are depicted. (C) HN5 Ctrl and ANXA1 KD1 cells were incubated in the
presence of 100-ng/ml recombinant EGF or 5% trehalose (Treh) as vehicle control for the indicated time points. Levels of total EGFR and
EGFR phosphorylated on tyrosine 1068 were determined by immunoblotting. Tubulin was used as loading control. The results of one
exemplary immunoblot (n Z 3) are depicted. (D) HN5 Ctrl and ANXA1 KD1 cells were incubated in the presence of 50 ng/ml re-
combinant EGF or 5% trehalose (Treh) as vehicle control for 1 h. Levels of total STAT3, phosphorylated STAT3 (Tyr705), total AKT,
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Fig. 3. (continued).
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was shown in HN5 and HSC3 by immunofluorescence
analysis with MCF-7 cells serving as positive control
(Suppl. S5), the HNSCC cell lines showed barely any
secretion of ANXA1 into the supernatant (Suppl. S4).
Addition of 100 nM recombinant ANXA1 to HN5 or
HN30 ANXA1 knockdown and control also did not
affect cellular proliferation rates (Fig. 1I). These findings
argue against a role of FPR2 signalling and support a
cell intrinsic effect of ANXA1 on cellular proliferation
in HNSCC.
3.2. ANXA1 regulates EGFR signalling
Annexin A1 is mainly known for its anti-inflammatory
activities but has also been suggested to influence
intracellular signalling pathways. When doing a
literature-based network reconstruction using Metacore,
a crosstalk between ANXA1 and EGFR signalling was
observed (Fig. 2A). EGFR is widely considered to bephosphorylated AKT (Ser473), phosphorylated ERK1/2 as well as An
loading control. The results of one exemplary immunoblot (nZ 3) are
the presence of 0.5, 5 or 50 ng/ml recombinant EGF with daily medium
were normalised to vehicle control (trehalose) and the mean  SEM o
ANOVA). (F) Cell viability of HN5 and HSC3 Ctrl as well as AN
cetuximab was assessed by MTT cell viability assay after the indicated
independent experiments. Differences observed in cell viability between
p-values are indicated (unpaired t-test; *: p < 0.05, **: p Z 0.005).one of the central drivers of oncogenesis in HNSCC [23].
Head and neck tumour samples were immunohis-
tochemically stained for ANXA1 and EGFR using
either an antibody targeting the internal or external
domain of the receptor (Fig. 2BeE). Interestingly, an
inverse relationship was observed for ANXA1 and
EGFR staining. While ANXA1 expression is compa-
rably high in the non-dysplastic area, EGFR expression
is low. In contrast to this, the tumour is characterised by
high levels of EGFR and almost undetectable ANXA1
expression. Correlation analysis confirmed the trend
towards an inverse correlation between (nuclear)
ANXA1 and EGFR in the head and neck tumour
samples analysed in this study. The correlation was seen
for 2 different antibodies targeting the external or in-
ternal domain of EGFR (adjusted r squared for
EGFRexternal Z 0.1869934 and for EGFRinternal Z
0.1665316) (Suppl. Fig. S6). Furthermore, ANXA1
knockdown indicated a change in the subcellular dis-
tribution of EGFR detected by immunofluorescence: thenexin A1 were determined by immunoblotting. Tubulin served as
depicted. (E) HN5 Ctrl and ANXA1 KD1 cells were incubated in
change. Cell viability was assessed 4 d later by MTT assay. Data
f 3 independent experiments is shown (n.s.: not significant, 2-way
XA1 KD1 cells in the presence of increasing concentrations of
time points. Data represent mean  SEM of 3 (HSC3) or 4 (HN5)
Ctrl and ANXA1 knockdown cells were statistically analysed and
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was more diffuse, and there was a clear decrease in
membraneous EGFR compared to control cells
(Fig. 3A). This hints at increased activation and intra-
cellular trafficking of EGFR in ANXA1 knockdown
cells.
We then studied the response of the ANXA1
knockdown cells towards EGFR stimulation. When
ANXA1 knockdown and control cells were incubated
for 30 min in the presence of 50 or 100 ng/ml recombi-
nant EGF, there was an increase in EGFR tyrosine 1068
phosphorylation in ANXA1 knockdown cells (Fig. 3B).
This increase in EGFR tyrosine 1068 phosphorylation
was stable over time and was maintained after 1 and 2 h
of receptor stimulation with 100 ng/ml recombinant
EGF (Fig. 3C). This indicates an increased and/or pro-
longed activation of EGFR receptor signalling in
ANXA1 knockdown cells. EGFR signalling is known to
control several different cellular signalling pathways
such as PI3 kinase/AKT, ERK and JAK/STAT signal-
ling pathways [30]. Phosphorylation and activation of
STAT3 and AKT was observed in the presence of re-
combinant EGF in both Ctrl and ANXA1 knockdown
cells. However, ANXA1 knockdown cells showed
increased phosphorylation of AKT at serine 473 after
receptor stimulation indicating increased activation of
the PI3 kinase/AKT pathway in these cells whereas
STAT3 signalling via STAT3 phosphorylation was
reduced (Fig. 3D). Of note, increased phosphorylation
of ERK1/2 was already observed in the absence of
stimulus in ANXA1 knockdown cells, which did not
further increase in response to EGF treatment indicating
EGF-independent ERK1/2 activation by ANXA1
downregulation. By contrast, control cells exhibited low
baseline levels of phosphorylated ERK1/2, and phos-
phorylation was upregulated in the presence of 50 ng/ml
recombinant EGF (Fig. 3D). It has already been re-
ported that EGF inhibits the growth of HN5 cells and
can induce senescence [45]. We confirmed the inhibitory
effect of EGF on wild-type HN5 cells by MTT assay;
however, ANXA1 knockdown HN5 cells had the ten-
dency to show increased survival in the presence of 5
and 50 ng/ml recombinant EGF (Fig. 3E) again sug-
gesting a regulation of the EGFR pathway by ANXA1.
Cetuximab, an IgG1 chimerised aEGFR monoclonal
antibody, binds with high affinity to the extracellular
EGF domain of EGFR and thereby prevents ligand
binding and receptor activation. ANXA1 knockdownFig. 4. Downregulation of ANXA1 changes exosome production levels
(EV) from cell culture supernatant of HN5 Ctrl, ANXA1 KD1 and Ha
nanoparticle tracking using Nanosight. The concentration of particles
mean  SEM of 3 independent experiments. (B) The overall concentr
supernatant was determined in the course of nanoparticle tracking
mean  SEM of 3 independent experiments (not significant, unpaire
exosomes in the vehicle, HN5 Ctrl and ANXA1 KD1 are shown belo
exosomal marker CD63 in the extracellular vesicles of HN5 Ctrl andand control cells were treated with increasing concen-
trations of cetuximab, and cell viability was assessed by
MTT assay. Interestingly, there was a trend towards
increased cetuximab sensitivity in HN5 and HSC3 cells
when ANXA1 was downregulated indicating a potential
EGFR-dependent response (Fig. 3F).
3.3. ANXA1 protein levels affect exosome production and
the release of exosomal phospho-EGFR
Recent findings have demonstrated an important role of
exosomal EGFR in metastasis formation. As ILVs can
be precursors of exosomes, we speculated that ANXA1
may regulate exosomal EGFR release [35,36]. Extra-
cellular vesicles of HN5 Ctrl and ANXA1 knockdown
cells were isolated by ultracentrifugation and charac-
terised by nanoparticle tracking analysis. When
measuring the concentration of particles per ml in
relation to the diameter of the particles in nm, there was
a difference in the distribution pattern of the particles
between the HN5 Ctrl and ANXA1 knockdown cells
(Fig. 4A). Particles of HaCat cells which are known to
secret high levels of exosomal EGFR served as positive
control, and the size of their exosomes peaked around
115 nm [46]. Interestingly, while exosomes of HN5 Ctrl
cells showed a bimodal size distribution with peaks at
approximately 115 nm and 140.5 nm, the peak at
115 nm was lost in HN5 ANXA1 knockdown cells
(Fig. 4A). Combined with the observation that HN5
ANXA1 knockdown cells tended to produce lower
levels of exosomes per ml (Fig. 4B), this indicates a
difference in exosome biogenesis and cargo release in
ANXA1-modulated cells. To investigate this in more
detail, the amount of exosomal phosphorylated EGFR
in these cells was analysed by immunoblotting. Down-
regulation of ANXA1 resulted in reduced levels of
exosomal phosphorylated EGFR (Fig. 4C). This further
supports an involvement of ANXA1 in cellecell
communication via exosomal EGFR.
4. Discussion
Current treatment strategies for head and neck cancer
are surgery and radiotherapy alone or in combination
with chemotherapy. These strategies are ineffective with
up to 50% of patients relapsing and are associated with
significant morbidity [38]. This highlights the need for
better predictive biomarkers and novel, more specificand exosomal phospho-EGFR content. (A) Extracellular vesicles
Cat cell lines were isolated by ultracentrifugation and analysed by
per ml was plotted against their bin centre in nm. Data represent
ation of isolated EV of HN5 Ctrl and ANXA1 KD1 cell culture
using Nanosight. Data represent particles per ml and depict
d t-test, p Z 0.4268). Video stills of exemplary measurements of
w the bar chart. (C) Levels of tyrosine 1068 phospho-EGFR and
ANXA1 KD1 cells were determined by immunoblotting (n Z 3).
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between oncogenic miR-196a and poor treatment
response in HNSCC patients. Further studies identified
ANXA1 as a direct target of the oncogenic microRNA
miR-196a potentially mediating therapy outcome [3]. In
this study we demonstrate a tumour suppressor role of
ANXA1 in HNSCC. ANXA1 was consistently down-
regulated in the analysed expression profiling data sets
and its expression levels negatively correlated with the
number of lymph nodes involved as well as the pathol-
ogy stage N as shown by Spearman correlation test.
Immunohistochemical staining of patient tumour sam-
ples detected substantially less ANXA1 in tumour
samples compared to adjacent normal tissue. Over-
expression of ANXA1 has been reported to have various
growth inhibitory effects such as cell cycle arrest and/or
apoptotic cell death in a range of cell lines through
various mechanisms [47e50]. We were unable to estab-
lish cell lines which transiently or stably overexpressed
ANXA1 despite using various techniques. This suggests
that the forced ANXA1 expression in HNSCC cell lines
induces a selective cell survival disadvantage and
consequently loss of the overexpressing clones. The re-
sults further support a tumour suppressive function of
ANXA1 in HNSCC.
The precise mechanism of ANXA1 downregulation in
HNSCC remains currently unclear. As mentioned above,
we have found ANXA1 to be a target for downregulation
bymiR-196a inHNSCC.AlthoughANXA1mutations are
a rare event in HNSCC, one of the mutations reported (at
aminoacid position 122) is a nonsensemutation resulting in
a truncated ANXA1 (http://www.tumorportal.org/view?
geneSymbolZANXA1,https://hive.biochemistry.gwu.ed
u/cgi-bin/prd/biomuta/servlet.cgi?gpageidZ11&searchfie
ld1Zgene_name&searchvalue1ZANXA1). Additionally,
chewing tobacco, which is one of the main risk factors of
oral cancer, results in the loss of the anti-inflammatory
activity of ANXA1 [20]. Collectively, these findings
identify ANXA1 as a potential predictive and prognostic
biomarker in HNSCC.
We have previously demonstrated that ANXA1
knockdown in HNSCC cell lines induces increased
tumour invasion and elevates the expression of EMT
markers [3]. ANXA1 is mainly an anti-inflammatory
protein with important roles in the innate and adap-
tive immune response [7]. Inflammation has been shown
to alter the tumour microenvironment as well as tumour
immune responses and to induce tumour hypoxia
[51,52]. Additionally, hypoxia induces a chronic in-
flammatory state which further reduces immune re-
sponses within the tumour microenvironment [53,54].
Considering the crucial role of ANXA1 in controlling
inflammation, it would be important to investigate
whether downregulation of ANXA1 in HNSCC results
in increased tumour hypoxia and more aggressive dis-
ease as well as therapy resistance in HNSCC. This is
particularly relevant as we initially identified miR-196a,which targets ANXA1, in HNSCC tumours with poor
treatment outcome which is also a hallmark of more
hypoxic cancers [3].
ANXA1 seems to have both pro- or anti-proliferative
activity depending on tumour types. Downregulation of
ANXA1 in oropharyngeal cancer as well as other cancer
subtypes has been described [15,55e58]. Surprisingly,
ANXA1 null mice show impaired tumour growth, and
specific subsets of breast cancers show upregulation of
ANXA1 [17,59]. The differences in ANXA1 activity
could be determined by different subcellular locations,
nuclear and membranous, and/or to its secreted and
intracellular forms [13]. So far, the tumour-associated
functions of ANXA1 have been mainly linked to a
paracrine/autocrine mechanism via secretion of ANXA1
and its interaction with its receptor FPR1 and/or 2 on the
cell surface [60]. However, in this study, no significant
levels of the secreted form of ANXA1were detected in the
HNSCC cell lines analysed. Our data therefore do not
support a major contribution of extracellular ANXA1
and paracrine/autocrine signalling pathways in control-
ling cellular proliferation in HNSCC. The findings here
suggest that the intracellular form of ANXA1 and its cell
autonomous effects on intracellular signalling pathways
may be important in regulating HNSCC tumour cell
growth and invasion [3]. One candidate signalling
pathway could be ERK1/2-mediated signalling as we
detected constitutively high levels of phosphorylated
ERK in the ANXA1 knockdown HNSCC cells as
compared to control cells. Interestingly, He et al. recently
showed that ANXA1 can decrease the nuclear accumu-
lation of phosphorylated ERK, which leads to reduced
expression of cyclin D1 and subsequent inhibition of
proliferation of rat pulmonary arterial smooth muscle
cells [48]. We also observed a decrease in STAT3 phos-
phorylation and thus STAT3 pathway activation in the
absence of ANXA1. Changes in ANXA1 expression
levels have already been reported to affect STAT3 acti-
vation positively or negatively depending on the type of
cancer. Silencing of another annexin superfamily mem-
ber, Annexin A2, has additionally been associated with
reduced EGF-induced STAT3 phosphorylation [61e63].
ANXA1 has been reported to regulate EGFR-
dependent signalling pathways [64]. Upregulation of
EGFR and increased EGFR phosphorylation is the
most common oncogenic event in HNSCC [65,66].
Elevated EGFR expression as well as gene amplification
has been shown to correlate with poor prognosis in
HNSCC and a variety of other cancer types such as
gastric, oesophageal, lung and triple negative breast
cancers [67e70]. Increased expression levels of EGFR
correlate with chemoresistance while lentiviral or
siRNA-mediated downregulation of EGFR expression
has been reported to enhance chemosensitivity in
HNSCC [71e73]. In recent years, multiple EGFR in-
hibitors have been developed, but cancer cells show
select sensitivity to these drugs. The inherent and/or
N. Raulf et al. / European Journal of Cancer 102 (2018) 52e68 65acquired resistance of cancers to EGFR inhibitors is
unclear and is under intense investigation. Mutations in
EGFR gene or changes in the subcellular localisation of
EGFR, resulting in inaccessibility of the inhibitor to the
receptor, could be a contributing factor. However, most
studies have focused on the cell autonomous EGFR
regulation as a cause of treatment resistance. Interest-
ingly, non-cell autonomous factors can also affect
sensitivity towards EGFR-targeting drugs such as
cetuximab. Van Dommelen et al., for example, reported
an association between cetuximab response and extra-
cellular vesicles [74]. It is known that EGFR signalling is
highly regulated by intracellular trafficking, and mole-
cules involved in this process can affect EGFR signalling
and EGFR localisation [32,75]. To this end, Annexin A1
has shown to be required for the formation of ILVs in
multivesicular bodies (MVBs) that sequester ligand-
bound EGFR away from the limiting membrane [21].
In this study, we show that downregulation of ANXA1
resulted in increased and sustained phosphorylation of
EGFR after EGF stimulation and that there was an
inverse correlation between ANXA1 and EGFR
expression levels in head and neck tumour samples.
Interestingly, sustained phosphorylation of EGFR at
tyrosine 1173, 845, and/or 1068 has been reported to
correlate with poor prognosis in HNSCC, and high
levels of EGFR phosphorylation facilitate metastasis in
salivary gland carcinomas [76e78]. Downregulation of
ANXA1 in combination with increased EGFR levels
and EGFR-dependent signalling could therefore
contribute to a malignant phenotype in HNSCC driving
cancer progression and invasion. Our data suggest that
one mechanism by which ANXA1 mediates its tumour
suppressive activities in healthy cells is via ensuring or-
dered and timely degradation of phosphorylated EGFR
and safeguarding regulated EGFR signalling pathway.
Given the role of ANXA1 in ILV formation and the
reports that ILVs are precursors of exosomes, we spec-
ulated that ANXA1 could also play a role in exosome
production in addition to its role in EGFR signalling
termination [33,79]. Here, we observed a reduction in
exosome production in HNSCC cell lines in response to
ANXA1 knockdown. Interestingly, decreased levels of
ANXA1 were also associated with disease progression.
To our knowledge, this is one of the first reports which
links disease progression and decreased activity of a
potential tumour suppressor (ANXA1) with reduced
exosome levels. So far, malignant cells and disease
progression have generally been associated with
increased exosome production [46,80]. Furthermore, our
findings indicate that it is rather specific cargo and not
general exosome levels that could be decisive for tumour
progression. Along these lines, we see the disappearance
of a subpopulation of exosomes in the analysed ANXA1
knockdown cells and an accompanying decrease in the
amount of exosomal phospho-EGFR. This hints at the
existence of different exosome biogenesis pathways.ANXA1 might be responsible for the recruitment of
phospho-EGFR into exosomes, and this might be
mediated by an (transient) interaction of ANXA1 and
phospho-EGFR which has already been reported [33].
Exosomal EGFR has been linked to organ-specific
metastasis by influencing premetastatic niche forma-
tion and to tumour immunity by inducing tolerance in
recipient dendritic cells and as a consequence tumour
antigen-specific regulatory T cells [36,37]. In summary,
ANXA1 seems to be located at the interface of inflam-
mation and cancer. The fact that cancer is considered as
‘wounds that do not heal’ highlights the importance of
balanced levels of anti-inflammatory proteins such as
ANXA1 [81]. Future studies will be important to
determine the impact of ANXA1-mediated reduction of
exosomal phospho-EGFR on tumour microenviron-
ment, hypoxia and tumour immunity.
5. Conclusion
Our studies support a tumour suppressive function of
ANXA1 in head and neck cancer. This role can mainly
be attributed to the intracellular version of the protein.
Intracellular ANXA1 seems to exert its activities cell
autonomously by affecting the strength and duration of
EGFR-dependent signalling events but also by regu-
lating exosomal phospho-EGFR release and thereby
cellecell communication. Further studies into the role of
ANXA1 in exosome production in general and exoso-
mal phospho-EGFR recruitment are required to fully
elucidate the ANXA1/EGFR axis and its importance in
HNSCC pathogenesis.
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